drugset / Trial / NCT05894837
Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
NaSingle-groupOpen-labelTreatment
Summary
A single-center, single-arm, phase 2 trial of Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion for third-line treatment in patients with colorectal cancer and liver metastases. A total of 30 patients are planned to be enrolled.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2024-06-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | — | — |
| Subject | Serplulimab | Monoclonal antibody | — | Intravenous |